IP Library Granted Patent US 9,283,242
Granted Patent B2
US 9,283,242 · App. 14/161,675 · Granted Mar 15, 2016

Uses of dihydro bases

Inventors: John M. Essigmann (Cambridge, MA); Deyu Li (Cambridge, MA); Katherine J. Silvestre (Seekonk, MA)
Assignee: Massachusetts Institute of Technology
A61K31/7076A61K31/708A61K31/7068A61K31/7072C07H19/073C07H19/173
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,283,242
App. No.
14/161,675
Granted
Mar 15, 2016
Kind
B2
Abstract

The present invention provides pharmaceutical compositions comprising a dihydro base described herein (e.g., compound DHdC). The dihydro base may show multiple tautomerism and may increase mutation of an RNA and/or DNA of a virus or cancer cell. The dihydro base may be used to reduce DNA methylation (e.g., in a cancer cell). The present invention also provides kits including the inventive pharmaceutical compositions and methods of treating a viral infection (e.g., influenza, HIV infection, or hepatitis C) or cancer using the pharmaceutical compositions or kits.

Claims (29)

1. A method of treating a viral infection in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising:

a compound of the formula:

or a pharmaceutically acceptable salt thereof; and

optionally a pharmaceutically acceptable excipient.

2. The method of claim 1 , wherein the viral infection is human immunodeficiency virus (HIV) infection, hepatitis C virus infection, respiratory syncytial virus (RSV) infection, Lassa fever virus infection, or poliovirus infection.

3. The method of claim 1 or 2 , wherein the subject is a human.

4. The method of claim 1 , wherein the pharmaceutical composition further comprises an additional pharmaceutical agent.

5. The method of claim 4 , wherein the additional pharmaceutical agent is an antiviral agent.

6. A method of increasing the mutation rate of a RNA of a virus, the method comprising contacting the virus with an effective amount of a pharmaceutical composition comprising:

a compound of the formula:

or a pharmaceutically acceptable salt thereof;

and optionally a pharmaceutically acceptable excipient;

and optionally an additional pharmaceutical agent.

7. A method of killing a virus, the method comprising contacting the virus with an effective amount of a pharmaceutical composition comprising:

a compound of the formula:

or a pharmaceutically acceptable salt thereof;

and optionally a pharmaceutically acceptable excipient;

and optionally an additional pharmaceutical agent.

8. A method of inhibiting replication of a virus, the method comprising contacting the virus with an effective amount of a pharmaceutical composition comprising:

a compound of the formula:

or a pharmaceutically acceptable salt thereof;

and optionally a pharmaceutically acceptable excipient;

and optionally an additional pharmaceutical agent.

9. The method of any one of claims 6 , 7 , and 8 , wherein the virus is human immunodeficiency virus (HIV), hepatitis C virus, respiratory syncytial virus (RSV), Lassa fever virus, or poliovirus.

10. A method of increasing the mutation rate of a DNA of a virus, the method comprising contacting the virus with an effective amount of a pharmaceutical composition comprising:

a compound of the formula:

or a pharmaceutically acceptable salt thereof;

and optionally a pharmaceutically acceptable excipient;

and optionally an additional pharmaceutical agent.

Assignments (2)
CONFIRMATORY LICENSE Recorded May 28, 2015
From: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035793/0436 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2014
From: ESSIGMANN, JOHN M.; LI, DEYU; SILVESTRE, KATHERINE J.
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 033115/0863 →
Continuity (2)
Provisional Application 61755459 · Jan 22, 2013
Related Publication 20140206639A1 · Jul 24, 2014